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Figure 1. Knees were mobilized on a CPM devise (A) or immobilized (B), ﬁxed
and examined for the presence of IL-1 by immuno-histochemical staining.
of PM was sufﬁcient for the suppression of proinﬂammatory
genes. Furthermore, the exposure of knees to extended periods
(8 h/day) of PM did not suppress proinﬂammatory gene induction
in the lesions irrespective of the cartilage damage from grade 1
to grade 4.
Conclusions: The expression of proinﬂammatory genes in this
study suggests that the ACL transected knee joint is susceptible
to enhanced degeneration when: (1) the cartilage damage is
greater than grade 2 as evidenced by the presence of proinﬂam-
matory gene expression in grade 3 and 4 lesions post PM and IM
treatment; and (2) the cartilage is exposed to extended periods
of PM or IM irrespective of the extent of cartilage damage (grade
1 to 4). However, low-intensity and low-impact exercise such
as PM may suppress or subside inﬂammation if the cartilage
damage is from grade 1 to 2, and the joint is stabilized during
mobilization. Further, the data suggest that IM treatment was
not able to limit inﬂammation by downregulating expression of
IL-1, MMP-1 and COX-2. Acknowledgements. This work was
supported by NIH grants AR48781 and HD040939.
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ARCHER STUDY: AN OPEN-LABEL TRIAL OF CHERRY
EXTRACT (ANTHOCYANINS) IN OSTEOARTHRITIS OF
THE KNEE
J.J. Cush1, E. Barnboym2, S. Zashin2
1Baylor Research Institute, Dallas, TX; 2Presbyterian Hospital,
Dallas, TX
Purpose: Montmorency (or Tart) cherries have long been
claimed to be a natural remedy for arthritis and gout. The poten-
tial therapeutic beneﬁt of cherry extracts containing ﬂavonoids
and anthocyanins has been suggested in laboratory models
demonstrating the antioxidant and anti-inﬂammatory (including
the inhibition of both cyclooxygenase 1 and 2) effects of cherry
extracts. Despite anecdotes from osteoarthritis (OA) and rheuma-
toid arthritis (RA) patients, this over-the-counter remedy has
never been formally studied. We have performed an open-label
trial of commercial gel-capsulated cherry extract (Cherry Flex
2000) in knee arthritis (ARCHER study). Each 400 mg soft gel
capsule contains 100 mg Anthocyanins, 20 mg ﬂavones and
30 mg Tannins. Also present are other antioxidants, melatonin,
isoqueritrin, queritrin, vitamin C, vitamin A, alpha linolenic acid
and traces of vitamin E, Beta carotene, folacin and thiamine.
Methods: This was a 20 patient 12 week trial of cherry extract
400 mg daily in patients with osteoarthritis of the knee. Inclu-
sion criteria included age > 40 yrs, active knee pain > 6mos,
a diagnosis of OA of the knee (using ACR clinical or radio-
graphic criteria) and informed consent to participate. Patients
were excluded if they required daily steroids, NSAIDs or narcotic
analgesics, had a history of signiﬁcant knee trauma or surgery
or a diagnosis of ﬁbromyalgia or inﬂammatory arthritis. Patients
were washed out of their NSAID or analgesic therapy and started
on cherry extract 400 mg/d. Rescue analgesia (acetaminophen)
was provided. Outcome variables included the WOMAC (total
and pain), patient and physician global assessment, patient pain,
patient and physician assessment of response, index joint ten-
derness and OA modiﬁed 28 tender joint counts.
Results: Two patients withdrew consent and 18 patients com-
pleted at least 8 weeks of daily cherry extract. This included
13 women and 5 males with a mean age of 55.1 years and
mean disease duration of 6.5 years. WOMAC pain subscales
and total scores improved >20% in 10/13 patients (56%). Similar
levels of improvement were noted for patient and MD global (50-
72%), HAQ, pain and Tender joint counts. WOMAC responders
improved by a mean of 61%. No substantive toxicities were ob-
served, as there was only 1 gastritis and 6 mild infections (URI,
UTI, ﬂu, sinusitis) noted.
Outcome Variable WOMAC Pt. Global MD Global Pain HAQ TJC Index Joint
% >20% improved 56 50 72 56 56 61 56
Conclusions: These interim, open-label results from the
ARCHER study suggest a moderate beneﬁt when a ﬁxed dose
OTC preparation of cherry extract is used in osteoarthritis of the
knee. A 2nd RCT will retest the utility of this compound and
whether a dose response effect may be seen in OA patients.
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SAFETY AND EFFICACY OF HUO-LUO-XIAO-LING (HLXL)
DAN IN OSTEOARTHRITIS OF THE KNEE
E.K. Pradhan1, B.M. Berman1, D.Y. Lee2, M.C. Hochberg1,
A.M. Gilpin1
1University of Maryland, Baltimore, MD; 2Harvard University,
Boston, MA
Purpose: Traditional Chinese Medicine (TCM) therapies, includ-
ing acupuncture, are increasingly used to treat patients with
symptomatic OA of the knee in Western societies. The scien-
tiﬁc basis for the use of herbal compounds in the treatment of
knee OA, however, is not as well developed. We have found that
the TCM herbal compound Huo-Luo-Xiao-Ling (HLXL) Dan has
signiﬁcant anti-inﬂammatory effects in a preclinical model of in-
ﬂammatory arthritis. Boswellic acids, including Boswellia carterii
(BC), are the main constituents of HLXL Dan, a Chinese herbal
mixture composed of 11 different herbal compounds. In addition,
there is evidence that boswellic acids are efﬁcacious in humans
with inﬂammatory arthritis. We report here the results of a Phase
I pilot study of HLXL Dan in adults with symptomatic knee OA.
Methods: A six-week phase I trial of HLXL Dan at a dose of
5180 mgs daily was conducted in 4 women and 3 men between
the ages of 41 and 72 years (Mean [±SD] 59 [±10] years) with
symptomatic knee OA. This IND study protocol was approved
by the Food and Drug Administration and by the University
of Maryland School of Medicine’s IRB. All participants gave
written informed consent. Participants were screened at week -
1, received HLXL Dan at week 0 (after eligibility was established),
and were then followed on weeks 1, 3, and 6. Average pain over
the past week was assessed with a 100 mm visual analogue
scale (VAS), and the patient’s global assessment of disease
was assessed on a 5-point Likert scale. Adverse events were
monitored by self-report and laboratory testing at all visits. Data
were analyzed in repeated measures mixed models in SAS.
Results: Adherence to the study protocol was high, with all
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subjects attending all assessment visits. There was one treat-
ment protocol termination; this subject discontinued HLXL Dan
after week 1 because of a rise in serum transaminase levels.
According to pill counts, overall compliance with study drug was
94 percent. There were no serious adverse events reported.
Overall, there was a signiﬁcant reduction in VAS knee pain that
was evident by week 3 and continued through the end of the
study (see Tables). While there was no signiﬁcant change in the
patient global assessment of disease during the intervention (P
= 0.37), 3 patients reported that they were markedly improved, 2
were moderately improved, and 1 each was slightly improved or
had no change at the ﬁnal visit.
Mean (SE) VAS Knee Pain
Baseline Week 1 Week 3 Week 6 Model F (df) P value
53.5 (5.2) 49.6 (5.2) 42.5 (5.4) 34.3 (5.4) 8.08 (16) 0.002
Mean (SE) Change in VAS Knee Pain
Period Mean (SE) P value
BL to WK 1 -3.9 (3.9) 0.34
BL to WK 3 -11.0 (4.2) 0.02
BL to WK 6 -19.2 (4.2) 0.0003
Conclusions: HLXL Dan at a single daily dose of 5,180 mgs
for six weeks was safe and efﬁcacious in this phase I study in
patients with symptomatic knee OA. A Phase II dose-ranging
placebo-controlled clinical trial of this herbal compound, sup-
ported by a grant from NCCAM, is currently being conducted.
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A COMPARISON OF TWO PHYSICAL THERAPY
PROGRAMS ON FUNCTIONAL CAPACITY,
PROPRIOCEPTION, AND BALANCE IN WOMEN WITH
KNEE OSTEOARTHRITIS
F. Erbahceci, E. Dursun
Hacettepe University, Ankara, Turkey
Purpose: Primary ﬁnding in knee osteoarthritis (OA) is gait
abnormalities. Also, decrease in muscle strength and range
of motion reduced functional capacity, impaired balance and
proprioception together with resultant increased risk of falling
have been reported. The purpose of this study was to investigate
the effects of two physical therapy and rehabilitation programs on
functional capacity, proprioception, and balance in women with
knee OA.
Methods: Forty female patients with knee OA participated in
this study. Patients were randomly and equally divided into two
groups. Group I underwent a physical therapy and rehabilitation
program consisting of hotpack, ultrasound, and proprioceptive
neuromuscular facilitation (PNF) exercises for a total 10 sessions,
5 days per week for 2 weeks. They continued PNF exercises for
3 days per week for additional 4 weeks. Group II underwent
hotpack, ultrasound, and isokinetic exercises for 5 days per
week, for 2 weeks (a total of 10 sessions). Similar to Group
I, they continued isokinetics exercises for 3 days per week for
additional 4 weeks. Patients were evaluated at baseline at the
second and the sixth weeks of treatment. Functional capacity
was evaluated using 15- meter walking distance, time up and go
test and 12- step up and down test. Proprioception was evaluated
using isokinetic dynamometer, and static and dynamic balance
was evaluated using kinesthetic ability trainer.
Results: Functional capacity, proprioception, and balance im-
proved signiﬁcantly in both groups (p<0.05). There were no
signiﬁcant differences between the groups in any of the variables
both at the second and the sixth week of treatment in any of the
groups (p>0.05).
Conclusions: Two different physical therapy and rehabilitation
programs had favorable effects on functional capacity, proprio-
ception and balance in women with knee OA. Therefore, both
programs can be used to improve these parameters in patients
with knee OA.
Therapy – Pharmacologic
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COMPARISON OF PHARMACOKINETICS OF
GLUCOSAMINE AND SYNOVIAL FLUID LEVELS
FOLLOWING ADMINISTRATION OF GLUCOSAMINE
SULPHATE OR GLUCOSAMINE HYDROCHLORIDE
M. Meulyzer, P. Vachon, F. Beaudry, T. Vinardell, H. Richard,
B. Guy, S. Laverty
Université de Montréal, St-Hyacinthe, PQ, Canada
Purpose: To compare the pharmacokinetics of glucosamine
following treatment with glucosamine sulphate or glucosamine
hydrochloride in a large animal model and to compare the syn-
ovial ﬂuid levels attained following the administration of each
formulation at clinically relevant doses.
Methods: Eight adult female horses were used. After an
overnight fast, crystalline glucosamine sulphate (Dona®) or glu-
cosamine hydrochloride were administered at a dose of 20 mg/kg
by either intravenous (IV) injection or nasogastric (NG) intuba-
tion. Plasma samples were collected before dosing and at 5,
15, 30, 60, 120, 360, 480 and 720 minutes after dosing. Syn-
ovial ﬂuid samples were collected from the radio-carpal joints
within 48 hours before dosing and at 1, 6 and 12 hours post
dosing. Glucosamine was measured in both plasma and syn-
ovial ﬂuid by Liquid Chromatography Electrospray Tandem Mass
Spectrometry (LC-ESI/MS/MS).
Results: Endogenous plasma and synovial glucosamine con-
centrations were not signiﬁcantly different and ranged between
< 10 ng/mL (LOQ) and 39.1 ng/mL. Following IV injection of
either compound, plasma concentrations reached ∼ 50 µg/mL
and declined in a similar multi-exponential fashion. After NG ad-
ministration, plasma concentrations attained ∼ 1 µg/mL for both
types of glucosamine with no signiﬁcant difference in attained
median maximal plasma concentrations. The median elimination
half-life of glucosamine after oral glucosamine sulphate admin-
istration was 4.0 hours and 3.0 hours after oral glucosamine
hydrochloride administration. The median oral bioavailability was
marginally but not signiﬁcantly higher for glucosamine sulphate
than for glucosamine hydrochloride and reached 9.4 % and 6.1 %
respectively. The AUC0-12hr and the AUC0-inf were signiﬁcantly
higher and the relative clearance was signiﬁcantly lower after
oral glucosamine sulphate treatment compared to glucosamine
hydrochloride treatment. The median maximal synovial ﬂuid con-
centrations were signiﬁcantly higher following oral treatment with
glucosamine sulphate (158.3 ng/mL) compared to oral adminis-
tration of glucosamine hydrochloride (88.9 ng/mL). The difference
in synovial ﬂuid concentrations attained following NG adminis-
tration was statistically signiﬁcant at 1 and 6 hours, but not at
12 hours post treatment. Twelve hours after oral treatment with
glucosamine hydrochloride, plasma and synovial glucosamine
levels had returned to baseline levels. Following oral adminis-
tration of glucosamine sulphate, glucosamine levels in plasma
and the synovial ﬂuid were still signiﬁcantly higher than base-
line twelve hours post-treatment. The difference in synovial ﬂuid
glucosamine concentrations attained between treatment groups
was not statistically signiﬁcant following IV treatment.
Conclusions: Following oral administration of a clinically rec-
ommended dose of glucosamine sulphate (Dona®), signiﬁcantly
higher synovial ﬂuid concentrations of glucosamine are attained,
